Galapagos (NASDAQ:GLPG) Sees Large Volume Increase - What's Next?

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) saw strong trading volume on Thursday . 192,635 shares traded hands during trading, an increase of 28% from the previous session's volume of 151,020 shares.The stock last traded at $26.34 and had previously closed at $26.65.

Wall Street Analysts Forecast Growth

GLPG has been the subject of a number of analyst reports. Leerink Partners assumed coverage on shares of Galapagos in a research note on Monday, September 9th. They set a "market perform" rating and a $24.00 target price for the company. Kepler Capital Markets lowered Galapagos from a "hold" rating to a "reduce" rating in a research report on Wednesday, November 20th. Royal Bank of Canada decreased their target price on Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a research note on Friday, November 1st. Finally, Leerink Partnrs raised Galapagos to a "hold" rating in a research note on Monday, September 9th. Two investment analysts have rated the stock with a sell rating and six have given a hold rating to the company's stock. According to MarketBeat, Galapagos currently has an average rating of "Hold" and an average target price of $30.75.

Galapagos Price Performance

The business has a fifty day moving average of $27.83 and a 200-day moving average of $27.37.

Institutional Investors Weigh In On Galapagos

Institutional investors and hedge funds have recently made changes to their positions in the business. AlphaCentric Advisors LLC raised its stake in shares of Galapagos by 3.3% in the second quarter. AlphaCentric Advisors LLC now owns 108,500 shares of the biotechnology company's stock worth $2,689,000 after purchasing an additional 3,500 shares during the last quarter. Signaturefd LLC raised its position in Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company's stock valued at $96,000 after buying an additional 1,258 shares during the last quarter. Rhumbline Advisers lifted its stake in Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 814 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in Galapagos by 25.4% during the 2nd quarter. Monaco Asset Management SAM now owns 20,999 shares of the biotechnology company's stock worth $520,000 after acquiring an additional 4,255 shares during the last quarter. Finally, Headlands Technologies LLC grew its stake in shares of Galapagos by 56.7% in the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 446 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.